Accéder au contenu
Merck

Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells.

Cell death and differentiation (2020-02-09)
In-Kyu Kim, Guanhua Rao, Xiaoliang Zhao, Ruzong Fan, Maria Laura Avantaggiati, Yisong Wang, Yu-Wen Zhang, Giuseppe Giaccone
RÉSUMÉ

The pathogenesis of thymic epithelial tumors (TETs) is poorly understood. Recently we reported the frequent occurrence of a missense mutation in the GTF2I gene in TETs and hypothesized that GTF2I mutation might contribute to thymic tumorigenesis. Expression of mutant TFII-I altered the transcriptome of normal thymic epithelial cells and upregulated several oncogenic genes. Gtf2i L424H knockin cells exhibited cell transformation, aneuploidy, and increase tumor growth and survival under glucose deprivation or DNA damage. Gtf2i mutation also increased the expression of several glycolytic enzymes, cyclooxygenase-2, and caused modifications of lipid metabolism. Elevated cyclooxygenase-2 expression by Gtf2i mutation was required for survival under metabolic stress and cellular transformation of thymic epithelial cells. Our findings identify GTF2I mutation as a new oncogenic driver that is responsible for transformation of thymic epithelial cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-α-tubuline, souris, clone DM1A, purified from hybridoma cell culture
Sigma-Aldrich
Anticorps anti-HA monoclonal antibody produced in mouse, clone HA-7, ascites fluid
Sigma-Aldrich
MISSION® esiRNA, targeting human PTGS2
Sigma-Aldrich
MISSION® esiRNA, targeting human PFKFB2